Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, First-In-Human, Dose-Escalation Study With Expansion to Assess the Safety, Tolerability, and Pharmacokinetics of Orally Administered TRE-515 in Subjects With Solid Tumors

NCT05055609 is registered in ClinicalTrials.gov with Trethera as lead sponsor.

NCT NCT05055609
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05055609 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, First-In-Human, Dose-Escalation Study With Expansion to Assess the Safety, Tolerability, and Pharmacokinetics of Orally Administered TRE-515 in Subjects With Solid Tumors
Lead sponsor
Trethera
Phase
Phase 1
Overall status
Recruiting
Start date
September 23, 2021
Completion date
June 1, 2027
Enrollment
94 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

oncology, solid tumor, adult